CA3112763C - Cd200r agonist antibodies and uses thereof - Google Patents

Cd200r agonist antibodies and uses thereof Download PDF

Info

Publication number
CA3112763C
CA3112763C CA3112763A CA3112763A CA3112763C CA 3112763 C CA3112763 C CA 3112763C CA 3112763 A CA3112763 A CA 3112763A CA 3112763 A CA3112763 A CA 3112763A CA 3112763 C CA3112763 C CA 3112763C
Authority
CA
Canada
Prior art keywords
antibody
seq
fcy
antigen binding
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3112763A
Other languages
English (en)
French (fr)
Other versions
CA3112763A1 (en
Inventor
Stephen John DEMAREST
Anja KOESTER
Payal Mehta
Scott Charles POTTER
Diana Isabel RUIZ
Derrick Ryan Witcher
Xiufeng Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA3112763A1 publication Critical patent/CA3112763A1/en
Application granted granted Critical
Publication of CA3112763C publication Critical patent/CA3112763C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3112763A 2018-09-14 2019-09-11 Cd200r agonist antibodies and uses thereof Active CA3112763C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731204P 2018-09-14 2018-09-14
US62/731,204 2018-09-14
PCT/US2019/050511 WO2020055943A1 (en) 2018-09-14 2019-09-11 Cd200r agonist antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CA3112763A1 CA3112763A1 (en) 2020-03-19
CA3112763C true CA3112763C (en) 2024-05-14

Family

ID=68051977

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3112763A Active CA3112763C (en) 2018-09-14 2019-09-11 Cd200r agonist antibodies and uses thereof

Country Status (27)

Country Link
US (2) US11319370B2 (https=)
EP (1) EP3849667A1 (https=)
JP (3) JP7185051B2 (https=)
KR (1) KR102705378B1 (https=)
CN (2) CN112739422B (https=)
AR (1) AR116668A1 (https=)
AU (1) AU2019339334B2 (https=)
BR (1) BR112021003254A2 (https=)
CA (1) CA3112763C (https=)
CL (1) CL2021000606A1 (https=)
CO (1) CO2021003093A2 (https=)
CR (1) CR20210134A (https=)
DO (1) DOP2021000040A (https=)
EA (1) EA202190530A1 (https=)
EC (1) ECSP21017619A (https=)
IL (1) IL281442B2 (https=)
JO (1) JOP20210048B1 (https=)
MA (1) MA53604A (https=)
MX (1) MX2021003026A (https=)
MY (1) MY196156A (https=)
NZ (1) NZ773626A (https=)
PE (1) PE20211742A1 (https=)
PH (1) PH12021550530A1 (https=)
SG (1) SG11202101697YA (https=)
TW (1) TWI749367B (https=)
WO (1) WO2020055943A1 (https=)
ZA (2) ZA202101246B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN116323665A (zh) 2020-05-29 2023-06-23 23和我公司 抗cd200r1抗体及其使用方法
PE20251170A1 (es) * 2022-04-06 2025-04-23 Mirobio Ltd Anticuerpos cd200r disenados por ingenieria y usos de estos
CN115458048B (zh) * 2022-09-16 2023-05-26 杭州美赛生物医药科技有限公司 基于序列编解码的抗体人源化方法
AU2024282979A1 (en) 2023-06-02 2026-01-22 Aimed Bio Inc. Anti-cd200r1 antibody and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368535B2 (en) * 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
HUE028179T2 (en) * 2006-01-12 2016-12-28 Alexion Pharma Inc Antibodies to OX-2 / CD200 and their use
KR20090094846A (ko) 2006-12-22 2009-09-08 쉐링 코포레이션 Ｃｄ200ｒ에 대한 항체
CA2786692A1 (en) * 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
WO2011100538A1 (en) * 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
WO2015057906A1 (en) 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists

Also Published As

Publication number Publication date
CO2021003093A2 (es) 2021-03-19
ECSP21017619A (es) 2021-04-29
JP7490025B2 (ja) 2024-05-24
NZ773626A (en) 2024-11-29
CA3112763A1 (en) 2020-03-19
EP3849667A1 (en) 2021-07-21
IL281442A (en) 2021-04-29
DOP2021000040A (es) 2021-03-31
SG11202101697YA (en) 2021-04-29
US11319370B2 (en) 2022-05-03
KR102705378B1 (ko) 2024-09-12
MY196156A (en) 2023-03-17
TW202024132A (zh) 2020-07-01
TWI749367B (zh) 2021-12-11
ZA202101246B (en) 2023-04-26
JOP20210048A1 (ar) 2021-03-11
CN118530360A (zh) 2024-08-23
AU2019339334B2 (en) 2023-03-09
JP2022500080A (ja) 2022-01-04
CR20210134A (es) 2021-03-29
MA53604A (fr) 2021-12-22
US20200087395A1 (en) 2020-03-19
ZA202204978B (en) 2022-09-28
WO2020055943A1 (en) 2020-03-19
AR116668A1 (es) 2021-06-02
BR112021003254A2 (pt) 2021-05-18
EA202190530A1 (ru) 2021-06-21
IL281442B1 (en) 2023-11-01
JP7185051B2 (ja) 2022-12-06
PE20211742A1 (es) 2021-09-06
KR20210044262A (ko) 2021-04-22
CL2021000606A1 (es) 2021-09-20
PH12021550530A1 (en) 2022-02-14
IL281442B2 (en) 2024-03-01
MX2021003026A (es) 2021-05-27
JOP20210048B1 (ar) 2024-12-22
JP2022141959A (ja) 2022-09-29
CN112739422A (zh) 2021-04-30
AU2019339334A1 (en) 2021-03-18
US20220251198A1 (en) 2022-08-11
JP2024105529A (ja) 2024-08-06
CN112739422B (zh) 2024-05-28

Similar Documents

Publication Publication Date Title
CN111886253B (zh) Pd-1激动剂抗体及其用途
CA3112763C (en) Cd200r agonist antibodies and uses thereof
JP6833798B2 (ja) 抗ｌａｇ−３結合タンパク質
JP7489922B2 (ja) 抗ｏｘ４０抗体及び使用方法
EP2187964B1 (en) High affinity human antibodies to human nerve growth factor
CN111712518B (zh) 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途
JP7072622B2 (ja) Ｂｔｌａアゴニスト抗体およびその使用
CA2930162A1 (en) Multifunctional antibodies binding to egfr and met
TW202146451A (zh) 抗人類cd19抗體
EA048233B1 (ru) Агонистические антитела к cd200r и их применение
CA3169155C (en) Anti-human cd19 antibodies
WO2024196694A2 (en) Pd-1 agonist antibodies and methods of treating inflammatory or autoimmune skin diseases with a pd-1 agonist antibody
EA043345B1 (ru) Антитела-агонисты btla и их применение
HK1144379B (en) High affinity human antibodies to human nerve growth factor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210312

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250821